genedrive plc
("genedrive" or the "Company")
Block Listing Returns
The Company confirms the block listing six monthly return for the period to 31 May 2023.
| Name of applicant | genedrive plc
| |||
| Name of scheme | 2007 Share Option Scheme
| |||
| Period of return: | From: | 01 December 2022 | To: | 31 May 2023 |
| Balance of unallocated securities under scheme(s) from previous return: | 139,226 shares
| |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 7,500 shares | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 131,726 shares
| |||
In order to co-terminate future block listing returns the Company confirms the following returns for the two block listings granted earlier in the month.
| Name of applicant | genedrive plc
| |||
| Name of scheme | 2017 Share Option Scheme
| |||
| Period of return: | From: | 19 May 2023 | To: | 31 May 2023 |
| Balance of unallocated securities under scheme(s) from previous return: | 1,150,588 shares
| |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,150,588 shares
| |||
| Name of applicant | genedrive plc
| |||
| Name of scheme | Unapproved Share Option Scheme
| |||
| Period of return: | From: | 19 May 2023 | To: | 31 May 2023 |
| Balance of unallocated securities under scheme(s) from previous return: | 2,668,144 shares
| |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,668,144 shares
| |||
| Name of contact: | Russ Shaw CFO | |||
| Telephone number of contact: | +44 (0)161 989 0245 | |||
For enquires:
| genedrive plc | +44 (0)161 989 0245 | |
| David Budd: CEO / Russ Shaw: CFO | | |
| | | |
| | | |
| Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 | |
| James Steel / Oliver Duckworth | | |
| | | |
| | | |
| finnCap (Joint Broker) | +44 (0)20 7220 500 | |
| Geoff Nash / George Dollemore / Nigel Birks / Alice Lane | | |
| | | |
| | | |
| Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com | |
| Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
| | | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
